Pulmonary embolism
Pulmonary embolism refers to a pathological and clinical condition caused by impacted materials entering the pulmonary artery and its branches, blocking the blood supply to the tissue. The most common emboli are blood clots, while others are rare neoplastic cells, fat droplets, air bubbles, intravenously injected drug particles, and even pulmonary vascular blockage caused by the tip of the catheter. Since the lung tissue is supplied with blood from both the bronchial artery and the pulmonary artery, and gas exchange can also be directly carried out between the lung tissue and the alveoli, most pulmonary emboli do not necessarily cause pulmonary infarction.
-
Site of disease:
lung -
Infectious :
Not contagious -
Frequent population:
All groups -
Related symptoms:
chest pain right heart failure cardiopulmonary embolism dyspnea acute dyspnea -
Concurrent disease:
Related Drugs
Urokinase for injection
Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases, including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6-12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3-6 hours, retinal artery embolism and other patients with severe iliac vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.
Manufacturer:
Tianjin Biochemical Pharmaceutical Co., Ltd.
Urokinase
Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6-12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3-6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.
Manufacturer:
Nanjing Nanda Pharmaceutical Co., Ltd.
Urokinase
Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6-12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3-6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.
Manufacturer:
Nanjing Nanda Pharmaceutical Co., Ltd.
Urokinase
Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6-12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3-6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.
Manufacturer:
Wuhan Humanwell Pharmaceutical Co., Ltd.
Dipyridamole Tablets
Indication: Used for thromboembolic diseases and ischemic heart disease.
Manufacturer:
CSPC OUYI Pharmaceutical Co., Ltd.
Urokinase for injection
Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6 to 12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3 to 6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.
Manufacturer:
Livzon (GROUP) Pharmaceutical FACTORY
Urokinase for injection
Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6 to 12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3 to 6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.
Manufacturer:
Livzon (GROUP) Pharmaceutical FACTORY
Urokinase for injection
Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6 to 12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3 to 6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.
Manufacturer:
Livzon (GROUP) Pharmaceutical FACTORY
Urokinase for injection
Indication: The product is mainly used for thrombolytic therapy of thromboembolic diseases, including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6-12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3-6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.
Manufacturer:
Tianjin Biochemical Pharmaceutical Co., Ltd.
Urokinase for injection
Indication: This product is mainly used for thrombolytic therapy of thromboembolic diseases. Including acute extensive pulmonary embolism, coronary artery embolism and myocardial infarction within 6 to 12 hours of chest pain, acute cerebral vascular embolism with symptoms shorter than 3 to 6 hours, retinal artery embolism and other patients with severe iliac-femoral vein thrombosis with peripheral arterial embolism symptoms. It is also used to prevent thrombosis after artificial heart valve surgery, maintain patency of vascular cannulation and chest and pericardial drainage tubes, etc. The efficacy of thrombolysis requires subsequent heparin anticoagulation to maintain.
Manufacturer:
Livzon (GROUP) Pharmaceutical FACTORY